A Study of DB-1310 in Advanced/Metastatic Solid Tumors
A phase 1/2 trial of Trastuzumab, Osimertinib and Capecitabine in advanced solid tumours, run by DualityBio Inc., now recruiting.
Overview
A Study of DB-1310 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05785741 by DualityBio Inc., with 1000 participants planned, started 2023-08-17 and due to reach its primary completion in 2027-12-30. Interventions recorded: DB-1310, Trastuzumab, Osimertinib and capecitabine.
Similar pages
not linked directly; found by shared links- TrialFirst-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Capecitabine, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor
Shares Capecitabine, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares Osimertinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSafety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
Shares Capecitabine, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.